Major trial tests cutting radiation for kids with hodgkin lymphoma
NCT ID NCT02684708
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large phase 3 trial enrolled over 2900 children and teens with classical Hodgkin lymphoma. The goal was to see if doctors could reduce the use of radiation therapy without lowering cure rates. Some patients also received stronger chemotherapy to make up for less radiation. The study aimed to find a balance that keeps survival high while reducing long-term harm from treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy (cyclophosphamide, vincristine, prednisone, dacarbazine, etoposide, doxorubicin)
- What this could lead to
- If successful, this could show that many children with Hodgkin lymphoma can be cured with less radiation, reducing long-term side effects.
- What could go wrong
- This trial is complete, but results may not apply to all patients. Reducing radiation might increase relapse risk in some groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHUV - Centre Hospitalier Universitaire Vaudois = LS, Départment femme - meré - enfant, Service de pédiatrie, Unité d'hématologie-oncologie pédiatrique
Lausanne, 1011, Switzerland
-
Clinic of Pediatric Oncology University Children's Hospital
Bratislava, 83340, Slovakia
-
Department of Medical Oncology Oslo University Hospital
Oslo, 0424, Norway
-
Department of Pediatric Hematology/Oncology (5054) The Child and Youth Clinic, University Hospital of Copenhagen
Copenhagen, 2100, Denmark
-
Dpt. of Pediatric Hematology and Oncology, Faculty Hospital Motol
Prague, 15006, Czechia
-
Head of Department of Pediatric Oncology and Hematology, Polish-American Pediatric Institute, Jagiellonian University Medical Faculty
Krakow, 30-663, Poland
-
Justus Liebig University of Giessen
Giessen, 35392, Germany
-
Our Lady's Children's Hospital, Crumlin
Dublin, 12, Ireland
-
Paediatric haemato-oncology, University Hospitals of Leuven
Leuven, 3000, Belgium
-
Pediatric Hematology & Oncology Children´s University Hospital
Uppsala, 75185, Sweden
-
Pediatric Radiotherapy and Youth Area Unit C.R.O. - Centro di Riferimento Oncologico IRCCS
Aviano, 33081, Italy
-
Princess Máxima Center for pediatric oncology
Utrecht, 3508, Netherlands
-
Royal Children's Hospital and Monash Medical Centre Royal Children's Hospital
Victoria Park, 3052, Australia
-
Sección de Onco-Hematología Pediátrica Hospital Universitario Virgen Macarena y Virgen del Rocío
Seville, 41071, Spain
-
Service d'Oncohématologie, Hopital d'Ènfants Armand Trousseau
Paris, 75571, France
-
St. Anna Kinderspital
Vienna, 1090, Austria
-
Starship Blood and Cancer Centre, Starship Children's Hospital
Auckland, 1142, New Zealand
-
Tel Aviv University Schneider Children's Medical Center of Israel The Rina Zaizov Pediatric Hematology Oncology Division
Petah Tikva, 49202, Israel
-
University College London Hospitals
London, NW1 2PG, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial